Form 4: Emergent BioSolutions Director Sells Shares for Tax

Emergent BioSolutions Director Donald W. DeGolyer sold 17,801 shares of common stock at a weighted average price of $10.54 to cover tax obligations related to RSU vesting.

Summary

• Director Donald W. DeGolyer of Emergent BioSolutions Inc. (EBS) sold 17,801 shares of common stock.
• The transaction occurred on November 10, 2025.
• The shares were sold at a weighted average price of $10.54 per share, with prices ranging from $10.33 to $10.79.
• The sale was executed under a Rule 10b5-1 trading plan established on August 11, 2025.
• The purpose of the sale was to satisfy tax obligations arising from the vesting of Restricted Stock Units (RSUs) on October 2, 2025.
• Following this transaction, Mr. DeGolyer beneficially owns 119,858 shares of common stock directly.

Sentiment

Score: 5

Explanation: Neutral. The sale is a routine insider transaction for tax purposes, pre-planned under a 10b5-1 plan, which mitigates negative sentiment often associated with insider sales. It does not reflect a change in company fundamentals or management's view of future prospects.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach rather than an opportunistic sale.
• The sale was explicitly for satisfying tax obligations related to RSU vesting, which is a common and often non-discretionary reason for insider sales.

Negatives

• A director selling shares, even for tax purposes, reduces their direct ownership stake in the company.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

This is an insider transaction report, which typically doesn't provide broader industry context. It reflects an individual's financial planning rather than a company-wide strategic move.

Related Party Transactions

• The transaction involves a director of the company, Donald W. DeGolyer, selling shares. This is a related party transaction, but it is a common and routine event for satisfying tax obligations related to equity compensation.

Stakeholder Impact

• Shareholders: The sale by a director reduces their direct ownership stake, but the stated reason (tax obligations from RSU vesting) under a 10b5-1 plan is a common and generally non-discretionary event, which typically has minimal impact on shareholder perception of company fundamentals.

Key Dates

Recommendation

The Form 4 filing details a routine insider sale by a director to cover tax obligations arising from RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction is common and typically does not signal a change in the company's fundamental outlook or the director's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and evaluate the company based on its broader financial performance and strategic developments.

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Trading, Stock Sale, Director, Donald W. DeGolyer, Rule 10b5-1, RSU Vesting, Tax Obligations